ストックスクリーナーアプリを入手
11.99
0.42%
-0.05
アフターアワーズ：
12.02
0.03
+0.25%
前日終値:
$12.04
開ける：
$12
24時間の取引高:
51,714
Relative Volume:
1.68
時価総額：
$2.06B
収益：
$549.97M
当期純損益:
$458.86M
株価収益率:
4.5701
EPS:
2.6236
ネットキャッシュフロー:
$-89.06M
1週間 パフォーマンス:
-4.16%
1か月 パフォーマンス:
-17.65%
6か月 パフォーマンス:
-14.36%
1年 パフォーマンス:
-9.65%
1日の値動き範囲:
$11.92
$12.12
1週間の範囲:
$11.72
$12.48
52週間の値動き範囲:
$11.72
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
11.99 | 2.07B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-11-24 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-05-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-03 | 開始されました | Jefferies | Buy |
| 2020-10-02 | 開始されました | Deutsche Bank | Buy |
| 2020-03-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 開始されました | Goldman | Buy |
| 2019-11-19 | 開始されました | CLSA | Buy |
| 2019-10-23 | 繰り返されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
すべてを表示
Hutchmed China Limited Adr (HCM) 最新ニュース
HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan
HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com
HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com
New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan
HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
HUTCHMED (Nasdaq: HCM) launches registrational Phase III HMPL-760 lymphoma trial in China - Stock Titan
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewswire Inc.
HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su - Stock Titan
HUTCHMED (China) Limited Sponsored ADR $HCM Stake Trimmed by Schroder Investment Management Group - MarketBeat
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
HUTCHMED (HCM) vests 726,317 LTIP shares to CEO and CFO - Stock Titan
TAZVERIK cancer drug withdrawn; HUTCHMED (HCM) ends China trials - Stock Titan
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - ChartMill
CLSA Cuts TP of HUTCHMED (00013.HK) to HKD30.4; Rating Outperform - AASTOCKS.com
Intended Retirement of Independent Non-executive Director and changes of composition of board committees - ChartMill
HUTCHMED (NASDAQ: HCM) plans INED retirement, reshapes board roles - Stock Titan
HUTCHMED H2 Earnings Call Highlights - Yahoo Finance
Food & Life Companies (3563.JP) Plunges 14% Following Alleged Parasite Egg Discovery at Beijing's Sushiro - AASTOCKS.com
[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan
HUTCHMED Reports 2025 Full Year Results and Business Updates - GlobeNewswire
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – What’s Next? - Defense World
Brokerages Set QCR Holdings, Inc. (NASDAQ:QCRH) PT at $102.25 - Defense World
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Analysts - MarketBeat
Hutchmed China Limited Adr (HCM) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):